Weiss A T, Rod J L, Gotsman M S, Lewis B S
Eur J Cardiol. 1981;12(5):261-70.
Hydralazine (Apresoline) was used to increase heart rate in 21 patients (14 hypertensive and 7 normotensive) suffering from symptomatic sinus bradycardia (SSB). Patients were assessed clinically and by 24-h ECG analysis before and after tailored increasing doses of the drug. Heart rates measured were resting (basal) rate, minimum rate during sleep, maximal rate during the day, and mean rate during the 24-h period (from hourly strips). The longest sinus pause or period of sinus arrest (when present) was also measured. Hydralazine ameliorated symptoms and produced a 20% or greater increase in heart rate in just under two-thirds of the hypertensive and half of the normotensive patients. Blood pressure decreased slightly in hypertensive but not in normotensive patients, and there were no important side-effects. Hydralazine appears to be a useful and effective drug to increase heart rate in patients with SSB.
肼屈嗪(阿普利素灵)用于提高21例有症状性窦性心动过缓(SSB)患者(14例高血压患者和7例血压正常者)的心率。在根据患者情况调整增加药物剂量前后,对患者进行了临床评估和24小时心电图分析。所测心率包括静息(基础)心率、睡眠期间最低心率、白天最高心率以及24小时期间(根据每小时记录)的平均心率。还测量了最长的窦性停搏或窦性静止期(如果存在)。在略少于三分之二的高血压患者和一半的血压正常患者中,肼屈嗪改善了症状并使心率增加了20%或更多。高血压患者血压略有下降,但血压正常患者血压未下降,且无严重副作用。肼屈嗪似乎是一种用于提高SSB患者心率的有用且有效的药物。